Altoida, Inc.

Altoida is a pioneer in developing digital biomarkers of neurological conditions, including Alzheimer’s Disease, using augmented reality and machine learning. Our technology platform is designed to enable an objective evaluation of an individual’s cognitive health and function, which may potentially allow for faster and more sensitive monitoring of disease progression and treatment response. Altoida is a privately-held, venture-backed, commercial stage company and our proprietary evidence-based platform is founded on more than 20 years of scientific research and published in multiple peer-reviewed papers including Nature Digital Medicine.